June 02, 2024 08:00 AM Eastern Daylight Time
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
View Full Size
Download
Full Size
JPEG, 1772x1749, 322.0 KB
Small
JPEG, 480x474, 82.6 KB
Preview
JPEG, 144x142, 37.8 KB
Thumbnail
JPEG, 71x70, 30.2 KB
Smart Multimedia Gallery
Share
Facebook
Twitter
LinkedIn
Delicious
Reddit
StumbleUpon
Digg
MySpace
Newsvine
Google Bookmark
Yahoo! Bookmark
Email
All News
|
News with Multimedia
>
Press Release: ENHERTU® Demonstrated a Median Progression-Free...
Get Business Wire News on Your Website
Terms of Use
|
© 2024 Business Wire